Literature DB >> 24399291

High expression of metabotropic glutamate receptor 4: correlation with clinicopathologic characteristics and prognosis of osteosarcoma.

Wu Yang1, He Maolin, Zhao Jinmin, Wang Zhe.   

Abstract

PURPOSE: Analyze protein and gene expression of mGluRs (mGluR1, mGluR5, mGluR4) in osteosarcoma tissues and discuss the relation between expression level and clinical characteristics of osteosarcoma, and study the clinical significance.
METHODS: Detect protein and mRNA expression level of mGluRs (mGluR1, mGluR5, mGluR4) in 40 osteosarcoma tissues and the corresponding adjacent normal tissues by Western blot and RT-PCR accordingly. Immunohistochemistry was adopted to detect the expression of mGluRs (mGluR1, mGluR5, mGluR4) in 118 paraffin embedded osteosarcoma tissues and eight normal bone tissues. Then, the correlation between the expression and clinical characteristics of patients was analyzed. Furthermore, survival analysis of osteosarcoma was performed to study the relation between expression level of mGluRs and patient prognosis.
RESULTS: No correlation of mGluR1 and mGluR5 with clinicopathologic characteristics of osteosarcoma was found. Statistical analysis demonstrated that the expression level of mGluR4 shared no significant correlation with gender, age, histologic type and tumor location of patient, but was related to Enneking stage and tumor metastasis (P < 0.05). High mGluR4 expression is more frequently noted in the osteosarcoma tissues with higher Enneking stage and metastasis. The results of Western blot and RT-PCR indicated a significantly increased expression level of mGluR4 gene and protein in osteosarcoma tissues compared with normal tissues. Though higher gene and protein expression of mGluR5 and mGluR1 were also indicated in osteosarcoma tissues compared with normal tissues, no statistical significance was noted for the difference (P > 0.05). According to the survival analysis of 118 osteosarcoma patients, cases in the mGluR4 high-expression group showed inferior disease-free survival rate and poorer overall survival rate.
CONCLUSION: High expression of mGluR4 in osteosarcoma tissues is related to poor prognosis, thus holding certain reference value for estimating prognosis of osteosarcoma patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24399291     DOI: 10.1007/s00432-013-1581-3

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  30 in total

Review 1.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 2.  The role of glutamate in the regulation of bone mass and architecture.

Authors:  T M Skerry
Journal:  J Musculoskelet Neuronal Interact       Date:  2008 Apr-Jun       Impact factor: 2.041

Review 3.  Osteosarcoma lung metastases detection and principles of multimodal therapy.

Authors:  Dorothe Carrle; Stefan Bielack
Journal:  Cancer Treat Res       Date:  2009

4.  Group-I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signalling pathways.

Authors:  Sukhwinder Thandi; Jonathan L Blank; R A John Challiss
Journal:  J Neurochem       Date:  2002-12       Impact factor: 5.372

5.  Evidence for a novel glutamate-mediated signaling pathway in keratinocytes.

Authors:  P G Genever; S J Maxfield; G D Kennovin; J Maltman; C J Bowgen; M J Raxworthy; T M Skerry
Journal:  J Invest Dermatol       Date:  1999-03       Impact factor: 8.551

6.  Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia.

Authors:  Pamela M Pollock; Karine Cohen-Solal; Raman Sood; Jin Namkoong; Jeffrey J Martino; Aruna Koganti; Hua Zhu; Christiane Robbins; Izabela Makalowska; Seung-Shick Shin; Yari Marin; Kathleen G Roberts; Laura M Yudt; Amy Chen; Jun Cheng; Arturo Incao; Heather W Pinkett; Christopher L Graham; Karen Dunn; Steven M Crespo-Carbone; Kerine R Mackason; Kevin B Ryan; Daniel Sinsimer; James Goydos; Kenneth R Reuhl; Michael Eckhaus; Paul S Meltzer; William J Pavan; Jeffrey M Trent; Suzie Chen
Journal:  Nat Genet       Date:  2003-05       Impact factor: 38.330

7.  Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice.

Authors:  Sam D Molyneux; Marco A Di Grappa; Alexander G Beristain; Trevor D McKee; Daniel H Wai; Jana Paderova; Meenakshi Kashyap; Pingzhao Hu; Tamara Maiuri; Swami R Narala; Vuk Stambolic; Jeremy Squire; Josef Penninger; Otto Sanchez; Timothy J Triche; Geoffrey A Wood; Lawrence S Kirschner; Rama Khokha
Journal:  J Clin Invest       Date:  2010-08-09       Impact factor: 14.808

8.  A family of metabotropic glutamate receptors.

Authors:  Y Tanabe; M Masu; T Ishii; R Shigemoto; S Nakanishi
Journal:  Neuron       Date:  1992-01       Impact factor: 17.173

9.  Cancer cell lines release glutamate into the extracellular environment.

Authors:  Eric P Seidlitz; Mohit K Sharma; Zeina Saikali; Michelle Ghert; Gurmit Singh
Journal:  Clin Exp Metastasis       Date:  2009-06-13       Impact factor: 5.150

10.  Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways.

Authors:  L Iacovelli; V Bruno; L Salvatore; D Melchiorri; R Gradini; A Caricasole; E Barletta; A De Blasi; F Nicoletti
Journal:  J Neurochem       Date:  2002-07       Impact factor: 5.372

View more
  10 in total

1.  Association of GRM4 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma in Guangxi Chinese population.

Authors:  Kun Wang; Jinmin Zhao; Maolin He; Mitra Fowdur; Tenglong Jiang; Shuju Luo
Journal:  Tumour Biol       Date:  2015-08-15

2.  Expression of metabotropic glutamate receptor 4 in osteosarcoma.

Authors:  Shuo Wang; Xing Wei; Bingyao Chen; Min Zhao; Guangze Song; Zengliang Zhang; Nan Li
Journal:  Mol Clin Oncol       Date:  2015-10-23

3.  High-level expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma.

Authors:  Fei Hu; Xi-Fu Shang; Wei Wang; Wei Jiang; Ce Fang; Dong Tan; Hang-Cheng Zhou
Journal:  Int J Exp Pathol       Date:  2016-03-30       Impact factor: 1.925

4.  Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole.

Authors:  Sally Liao; Yuleisy Ruiz; Hira Gulzar; Zarina Yelskaya; Lyes Ait Taouit; Murielle Houssou; Trisha Jaikaran; Yuriy Schvarts; Kristina Kozlitina; Upal Basu-Roy; Alka Mansukhani; Shahana S Mahajan
Journal:  PLoS One       Date:  2017-02-23       Impact factor: 3.240

5.  Prediction and Identification of GPCRs Targeting for Drug Repurposing in Osteosarcoma.

Authors:  Manli Tan; Shangzhi Gao; Xiao Ru; Maolin He; Jinmin Zhao; Li Zheng
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

6.  High expression of periostin is dramatically associated with metastatic potential and poor prognosis of patients with osteosarcoma.

Authors:  Fei Hu; Wei Wang; Hang-Cheng Zhou; Xi-Fu Shang
Journal:  World J Surg Oncol       Date:  2014-09-15       Impact factor: 2.754

7.  To Explore the Mechanism of the GRM4 Gene in Osteosarcoma by RNA Sequencing and Bioinformatics Approach.

Authors:  Yunguo Pang; Jinmin Zhao; Mitra Fowdur; Yun Liu; Hao Wu; Maolin He
Journal:  Med Sci Monit Basic Res       Date:  2018-01-17

8.  Activity of Metabotropic Glutamate Receptor 4 Suppresses Proliferation and Promotes Apoptosis With Inhibition of Gli-1 in Human Glioblastoma Cells.

Authors:  Zhichao Zhang; Xiaoyan Zheng; Yan Luan; Yingfei Liu; Xingxing Li; Chongxiao Liu; Haixia Lu; Xinlin Chen; Yong Liu
Journal:  Front Neurosci       Date:  2018-05-15       Impact factor: 4.677

9.  Clinical significance of glutamate metabotropic receptors in renal cell carcinoma risk and survival.

Authors:  Chao-Yuan Huang; Yu-Mei Hsueh; Lih-Chyang Chen; Wei-Chung Cheng; Chia-Cheng Yu; Wei-Jen Chen; Te-Ling Lu; Kuo-Jin Lan; Cheng-Hsueh Lee; Shu-Pin Huang; Bo-Ying Bao
Journal:  Cancer Med       Date:  2018-11-28       Impact factor: 4.452

10.  Comprehensive metabolomic profiling of osteosarcoma based on UHPLC-HRMS.

Authors:  Dongming Lv; Yutong Zou; Ziliang Zeng; Hao Yao; Shirong Ding; Yiying Bian; Lili Wen; Xianbiao Xie
Journal:  Metabolomics       Date:  2020-11-18       Impact factor: 4.290

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.